Georgia's Online Cancer Information Center


back

Ovarian Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Ovarian Cancer
Cancer Type = Ovarian Cancer
NCI ID Cancer Type Trial Name
There are currently 23 active Ovarian Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
9-ING-41 in Patients With Advanced Cancers
Cancer Type
Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT03678883
Protocol IDs
1801
NCI-2018-03166
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cancer Type
Colon/Rectal Cancer, Ovarian Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer
NCT ID
NCT05360680
Protocol IDs
CUE-102-01
NCI-2022-05169
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Cancer Type
Breast Cancer, Cervical Cancer, Gynecologic Cancers, Head and Neck Cancer, Ovarian Cancer
NCT ID
NCT04682431
Protocol IDs
PY159-2-01
NCI-2021-01998
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Ovarian Cancer
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
6.
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT04092270
Protocol IDs
10324
10324
NCI-2019-06123
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Cancer Type
Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer
NCT ID
NCT02922764
Protocol IDs
RGX-104-001
NCI-2017-00226
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
NCORP Trial
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type
Ovarian Cancer
NCT ID
NCT04251052
Protocol IDs
NRG-CC008
NRG-CC008
NRG-CC008
NCI-2019-07791
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
9.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Gynecologic Cancers, Ovarian Cancer, Prostate Cancer
NCT ID
NCT04972981
Protocol IDs
ADCT-901-101
NCI-2021-10797
2021-002292-19
10.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
11.
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT03188965
Protocol IDs
18594
NCI-2018-00206
2016-004484-39
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03401385
Protocol IDs
DS1062-A-J101
NCI-2018-01200
173812
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT03319628
Protocol IDs
XMT-1536-1
NCI-2018-00402
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
IMGN853 With Carboplatin in Second-line Treatment of FRa Expressing, Platinum-sensitive Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05456685
Protocol IDs
IMGN853-0420
NCI-2022-09869
2022-002034-14
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
16.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
17.
NCORP Trial
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT04498117
Protocol IDs
QPT-ORE-005
NCI-2020-08028
FLORA5
FLORA-5
GOG 3035
GOG-3035
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
18.
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Melanoma, Ovarian Cancer
NCT ID
NCT05585034
Protocol IDs
XmAb808-01
NCI-2023-00610
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
20.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Ovarian Cancer
NCT ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
21.
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Cancer Type
Breast Cancer, Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04726332
Protocol IDs
XL102-101
NCI-2021-03620
22.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05276973
Protocol IDs
NRG-GY027
NRG-GY027
NCI-2022-01930
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
23.
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Cancer Type
Ovarian Cancer
NCT ID
NCT05329545
Protocol IDs
XMT-1536-3
NCI-2022-04396
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.